Considering that low-dose OX, but not CIS, showed synergistic antitumor effects with TIGIT blockade, we hypothesized that low-dose OX sensitized colon tumors to checkpoint blockade therapy. The gene discussed is TIGIT; the disease is colonic neoplasm.